• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

    1.130 +0.050 (+4.63%)
    Streaming Delayed Price Updated: 10:56 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Allarity Therapeutics, Inc. - Common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
    Via AB Newswire
    Topics Government
    News headline image
    Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Changes to Board of Directors
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.